Bioxytran Stock

Bioxytran Equity

The The Equity of Bioxytran (BIXT) as of Aug 15, 2026 is -2.76 M USD. In the previous year, The Equity was -2.83 M USD — a change of -2.42% (higher).

Equity

-2.76 MUSD

YoY

-2.42%

Last updated:

In 2026, Bioxytran's equity was -2.76 M USD, a -2.42% increase from the -2.83 M USD equity in the previous year.

Access this data via the Eulerpool API

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bioxytran's Equity

Bioxytran's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bioxytran's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bioxytran's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bioxytran's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bioxytran’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bioxytran stock

The Equity of Bioxytran is -2.76 M USD in 2026.

The Equity of Bioxytran changed from -2.83 M USD to -2.76 M USD, representing a -2.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bioxytran since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bioxytran historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bioxytran

All Key Metrics — Bioxytran